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A B S T R A C T
A new method using high-performance liquid chromatography coupled with ultra violet detection (HPLC–UV)
was developed and validated for the simultaneous quantiﬁcation of atazanavir, dolutegravir, darunavir,
efavirenz, etravirine lopinavir, raltegravir, rilpivirine and tipranavir in human plasma. For the ﬁrst time we
reported here the development and validation of an HPLC–UV assay to quantify the frequently administered 9
antiretroviral compounds including dolutegravir and rilpivirine. A simple solid phase extraction procedure was
applied to 500 µL aliquots of plasma. The chromatographic separation of the drugs and internal standard
(quinoxaline) was achieved with a gradient of acetonitrile and sodium acetate buﬀer on a C18 reverse-phase
analytical column with a 25 min analytical run time. Calibration curves were optimised according to the
therapeutic range of drug concentrations in patients, and the coeﬃcient of determination (r2) was higher than
0.99 for all analytes. Mean intraday and interday precisions (RSD) for all compounds were less than 15.0%, and
the mean accuracy (% deviation from nominal concentration) was also found to be less than 15.0%. Extraction
recovery range was between 80% and 120% for all drugs analysed. The solid phase extraction and HPLC–UV
method enable a speciﬁc, sensitive, and reliable simultaneous determination of nine antiretroviral agents in
plasma. Good extraction eﬃciency and low limit of HPLC–UV quantiﬁcation make this method suitable for use
in clinical trials and therapeutic drug monitoring.
1. Introduction
The use of combination antiretroviral therapy (HAART) has
improved markedly the survival of HIV-1 infected patients such that
the life expectancy of HIV-infected patients aged 20 years was
projected to increase from 36.1 years to 49.4 years, according to the
various multinational cohort studies [1]. Despite marked increases in
life expectancy, mortality rates among HIV-infected persons remain 3–
15 times higher than those seen in the general population [2]. Although
some of the excess mortality observed among HIV-infected persons can
be directly attributed to illnesses that occurred as a consequence of
immunodeﬁciency, more than half of the deaths observed in recent
years among HAART-experienced HIV-infected patients were attribu-
table to non-infectious comorbidities [3,4].
Prolonged exposure to antiretroviral therapy along with aging may
increase the risk of developing metabolic complications and cardiovas-
cular diseases among HIV-infected patients. Several studies have
provided evidence that comorbidities such as diabetes mellitus [5–7],
hypertension [5,8], coronary artery disease [5,6], hyperlipidemia [5,7],
renal disease [9] and reduced bone mineral density [10] happen more
frequently among HIV-infected elderly patients than in HIV-uninfected
controls. In addition to HAART, medications for management of
metabolic and other complications further increase the pill burden
and potential for drug-drug interactions in the elderly patients [11].
Further treatments may also be required for other indications includ-
ing hepatitis co-infections, psychiatric illnesses, oncology diagnoses
and solid-organ transplantations. Finally, patients may also take
vitamins, food supplements, complementary/alternative medicine
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(CAM), or recreational agents on a regular or occasional basis. These
factors further enhance the drug-drug interaction possibilities.
Negative consequences of drug interactions include viral break-
through and development of resistance, sub-optimal disease/symptom
management, drug toxicity and possible non-adherence. Because of the
poly-pharmacy treatment in HIV, it is advisable to have simultaneous
methods for fast and friendly quantiﬁcation of antiretroviral drugs in
diﬀerent matrices.
Many methods for the simultaneous quantiﬁcation of various
antiretroviral drugs using high-performance liquid chromatography
with UV detection (HPLC–UV) have been published [12–19]. Liquid
chromatography coupled with tandem mass spectrometry (LC–MS/
MS) has been used to quantify dolutegravir (DTG) and rilpivirine
(RPV) in plasma samples [20–26]. However, higher cost of the
instruments and their maintenance, as well as the technical assistance
limited the use of LC–MS in clinical laboratories of hospitals. HPLC–
UV represents a cheaper option and is easier to adapt to the hospital
setting. As far as we know, no HPLC–UV methods for the simultaneous
quantiﬁcation of atazanavir (ATV), DTG, darunavir (DRV), efavirenz
(EFV), etravirine (ETV), RPV, raltegravir (RGV), lopinavir (LPV), and
tipranavir (TPV) in human plasma have been published to date.
The aim of our study was to develop and validate an HPLC–UV
method for the simultaneous quantiﬁcation of the new drugs, DTG and
RPV, together with 7 frequently used antiretroviral drugs in human
plasma samples.
2. Experimental
2.1. Chemicals and reagents
ATV, DTG, EFV, ETV, LPV, and RGV standard powders were
purchased from Spectra 2000 (Rome, Italy); DRV and RPV were kindly
provided by Janssen Cilag (Beerse, Belgium); TPV was donated by
Boehringer Ingelheim Pharmaceuticals; and quinoxaline (QX), used as
internal standard (IS), was purchased from Sigma (Milan, Italy).
Acetonitrile and methanol (Sigma) were of HPLC grade. Deionised
water used in all aqueous solutions was obtained from a Milli-Q water
puriﬁcation system (Millipore, Milan, Italy).
Stock solutions with a concentration of 1 mg/mL were prepared for
ATV, DRV EFV, ETV, LPV, RGV, and TPV in methanol. Stock solutions
with a concentration of 1 mg/mL were prepared for DTG in methanol/
dimethylsulfoxide (98:2, v/v) and for RPV in methanol/dimethylsulf-
oxide (90:10, v/v). A working solution of IS was made with QX
(7.5 mg/mL) in methanol and stored at 4 °C until use.
2.2. Calibration curve and quality control samples
Calibration samples (500 µL) were prepared through mixing appro-
priate volumes of analytes working solutions with plasma from healthy
volunteers to achieve six diﬀerent concentrations as shown in Table 1.
Quality control samples (QCs) (500 µL) were prepared by adding a
determined volume of stock solution to blank plasma to obtain three
concentration levels (low, medium and high) within the linear con-
centration (Table 1). The QC samples were stored frozen at −20 °C
until analysis.
Two calibration curves of 6 standard (STD) points were made due
to the coelution of DTG with RGV and EFV with LPV. Calibration curve
A was made with DTG, DRV, ATV, ETV, RPV, TPV and EFV and
calibration curve B was made with RPV, ETV, RGV, DRV, ATV, LPV
and TPV. Calibration ranges, from STD 6 to STD 1, and QC concentra-
tions for all drugs are listed in Table 1.
2.3. HPLC–UV apparatus and conditions
The chromatographic system consisted of an Alliance e2695
Separation Module equipped with an online degasser and an automatic
injector maintained at 10 °C as well as a 2998 photodiode array
detector, set at 260 nm for the detection of ATV, DRV, DTG, EFV,
LPV, RGV and TPV and at 305 nm for ETV and RPV. Data were
collected and processed using Empower software for HPLC system
(Waters, Milan, Italy).
Separations were performed on an XBridge C18 (4.6 mm×150 mm,
3.5 µm; Waters) column equipped with a Sentry (4.6 mm×10 mm;
Waters) guard column. Both columns were maintained at 35 °C. The
mobile phase consisted of acetonitrile (solvent A) and 50 mM acetate
buﬀer at pH 4.5 (solvent B) delivered at a ﬂow rate of 1 mL/min. A
gradient elution was applied: 40% of solvent A was maintained for
9 min, then raised in 7 min to 70%. A re-equilibration step was
included and the total run time was 25 min.
2.4. Sample preparation
Patients receiving standard doses of diﬀerent antiretroviral drugs
underwent blood sampling after obtaining their informed consent for
the measurement of plasma drug concentrations. 5 mL blood samples
were collected in EDTA tubes and plasma was obtained after centrifu-
gation at 3000 rpm for 10 min at 4 °C (Sigma 3–16PK). Plasma
samples were then underwent heat inactivation procedure for HIV
(35 min at 58 °C). To avoid thawing cycles, each patient plasma sample
was aliquoted into micro tubes of 2 mL and stored at −20 °C until
analysis. On the day of analysis an aliquot of 500 µL of plasma samples
was pipetted into labelled disposable polypropylene eppendorf tubes
and 50 µL of IS solution was added. The tubes were vortex-mixed for
30 s, and then 500 µL of 50 mM acetate buﬀer at pH 4.5 was added, for
protein precipitation. The tubes were vortex-mixed for further 60 s and
centrifuged at 10,000g for 10 min at 4 °C.
Table 1.
Retention time, UV wavelengths, calibration points and QC concentrations.
Analyte Retention time (min) Wavelengths (nm) Calibration points (ng/mL) QC (ng/mL)
STD1 STD2 STD3 STD4 STD5 STD6 Low Medium High
ATV 15.3 260 60 180 600 1800 6000 12,000 90 900 2000
DTGa 5.4 260 20 60 200 800 4000 8000 50 300 2000
DRV 9.6 260 150 300 900 3000 6000 15,000 600 1800 8000
EFVa 17.1 260 150 300 900 3000 6000 15,000 600 1800 8000
ETV 17.4 305 50 100 500 1000 2000 4000 200 1600 3000
LPVb 17.4 260 150 300 900 3000 6000 15,000 600 1800 8000
RGVb 5.6 260 40 120 400 1200 4800 9600 80 600 6000
RPV 13.8 305 20 60 200 400 600 2000 50 300 1000
TPV 18.7 260 500 1000 5000 10,000 20,000 40,000 2000 16,000 30,000
Internal standard 8.6 260 – – – – – – – – –
a DTG and EFV were only present in calibration curve A due to its co-elution with RGV and LPV, respectively.
b LPV and RGV were only present in calibration curve B due to its co-elution with EFV and DTG, respectively.
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Solid phase extraction (SPE) C18 cartridges were placed on a Vac
Elut 20 Manifold (Agilent Technologies) and activated with 1 mL of
methanol followed by 1 mL of HPLC solvent B before sample loading.
Loading was carried out under gravity. The cartridges were then
washed with 500 µL of HPLC solvent B, followed by 250 µL of HPLC
grade water and then elution was carried out using 1 mL of methanol
and acetonitrile solution (90:10, v/v). Eluted solution was collected
into a polypropylene tube and dried at 50 °C in a model Speedvac
centrifugal evaporator (Bioinstruments, Italy). The residue was re-
suspended in 150 µL of H2O:CH3CN (60:40, v/v), centrifuged, ﬁltered
and then transferred to polypropylene vials. 30 µL sample was then
injected into the HPLC system.
2.5. Method validation
2.5.1. Speciﬁcity and selectivity
Interference from endogenous compounds was investigated by
analysis of diﬀerent blank plasma samples. Potential interference by
antiretroviral drugs concomitantly administered to the patients was
also evaluated by spiking blank plasma with them. To test potential
concomitant medication or xenobiotic interference, plasma samples
from 30 patients given diﬀerent combinations of anti-HIV drugs
(together with abacavir, lamivudine, tenofovir, ritonavir, amprenavir,
zidovudine, nelﬁnavir, maraviroc), antibiotics (linezolid, vancomycin,
gentamicin, rifampicin, levoﬂoxacin), or antifungal agents (voricona-
zole, posaconazole) were used for the analysis.
2.5.2. Accuracy, precision, calibration, and limit of quantiﬁcation
Intraday and interday accuracy and precision were determined by
assaying 6 spiked plasma samples at 3 diﬀerent concentrations (QCs)
for all drugs. Accuracy was calculated as the percent deviation from the
nominal concentration. Interday and intraday precisions were ex-
pressed as the relative standard deviation (RSD) at each QC concen-
tration. Each calibration curve was obtained using 6 calibration points,
the ranges of which are listed in Table 1. Calibration curves were
constructed by linear least-squares regression (1/x2 weighting) of peak
height ratios (analyte/IS) versus nominal concentrations. The method
has a good linearity if the coeﬃcient of regression (r2 ) calculated as
mean of 10 curves was ≥ 0.99 [27]. The calibration curves for
estimating all the drugs concentrations in unknown samples consisted
of six concentrations of plasma samples. These samples were prepared
in every analysis together with a blank plasma sample.
The within-day and between-day coeﬃcient of variation (CV) and
the accuracy of the method were assessed by calculating daily and
overall CVs and bias values for QC (ﬁve replicates at each concentration
per analytical run) that were assayed in 5 separate analytical runs. The
assay was considered acceptable if CV at each concentration was < 15%
for both within-and between-day variability and the deviation of the
mean from the true value was within ± 15% [27]. The lowest identiﬁ-
able peak that yielded a signal to noise ratio of 10:1 with a reproducible
concentration (imprecision of 20% and accuracy of 80%–120% for each
analyte) was accepted as limit of quantiﬁcation (LOQ) and was set as
the ﬁrst calibration curve point (Table 1).
2.5.3. Recovery
Recovery from plasma, using the extraction procedures, was
assessed by comparing the peak height ratio obtained from multiple
analyses of spiked plasma samples (QCs) with the peak height ratio
from direct injections of the same amount of all analytes and IS. The
Fig. 1. Representative chromatograms of standard point 1 and blank plasma of (A)
calibration curves A and (B) calibration curves B at 260 nm and (C) RPV and ETV at
305 nm.
Fig. 2. Comparative chromatograms of standard point 6 and standard point 1 of (A)
calibration curves A and (B) calibration curves B at 260 nm and (C) RPV and ETV at
305 nm.
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assay was accepted if recovery exceeded 80%.
2.5.4. Stability
Drug stability in plasma samples was studied as per the FDA
guidelines [27]. Stability studies evaluated the stability of all the
analytes during sample collection and handling, after long-term
(intended storage temperature) and short-term (bench-top, room
temperature) storage, after going through freeze and thaw cycles and
the analytical process. The freeze-thaw stability was determined after
three freeze-thaw cycles of freezing at –60 °C for 24 h and then thawing
completely at room temperature. The stability of extracted samples at
20 °C in the autosampler was evaluated up to 24 h after extraction. The
long-term stability was evaluated using QC samples that were stored at
−60 °C for at least 3 months.
2.6. Patients samples analysis
In order to ascertain accuracy when measuring clinical samples, our
laboratory participated in an external quality assurance programme
(KKGT, Radbound University Medical Centre, Nijmegen, The
Netherlands) [28]. The developed method has been routinely used
for the therapeutic drug monitoring (TDM) of ATV, DRV, DTG, ETV,
EFV, LPV, RGV, RPV and TPV and for the optimisation of HAART
therapy for HIV-infected patients.
3. Results
Retention time of all the analytes are shown in Table 1. Retention
time of DTG and EFV was found to be close to that of RGV and LPV,
respectively. Furthermore, LPV and ETV even had the same retention
time. For this reason, 2 diﬀerent lots of the STD and the QCs were
made. DTG, DRV, RPV, ATV, EFV, ETV and TPV were present in
calibration curve A while RGV, DRV, RPV, ATV, LPV, ETV and TPV
were present in calibration curve B. The use of two wavelengths for LPV
and ETV permits to quantify the two analytes concomitantly in a
precise way, the absorbance at the other wavelength is in fact
negligible. Representative chromatograms of STD 1 and blank plasma
of calibration curve A, calibration curve B at 260 nm, and ETV and RPV
at 305 nm are shown in Fig. 1. The comparative chromatograms of STD
6 and STD 1 of calibration curves A and calibration curves B at 260 nm,
and ETV and RPV at 305 nm are shown in Fig. 2. Mean regression
coeﬃcient of determination (r2) of all calibration curves was better
Table 2.
Intraday and interday precision study.
Analyte Level Intraday Interday
Mean ± SD (ng/mL) RSD (%) Accuracy (%) Mean ± SD (ng/mL) RSD (%) Accuracy (%)
ATV LOQ 60.3 ± 7.1 11.7 100.5 63.3 ± 6.8 10.7 105.5
LQC 90.9 ± 6.7 7.3 101.0 99.7 ± 6.6 6.7 110.8
MQC 875 ± 65 7.4 97.2 964 ± 57.4 5.9 107.1
HQC 2170 ± 281 12.9 108.5 1815 ± 79 4.3 90.7
DTG LOQ 19.9 ± 1.6 8.1 99.6 19.9 ± 0.3 1.5 99.8
LQC 46.7 ± 2.9 6.1 93.5 53.7 ± 6.8 12.7 107.4
MQC 337 ± 21 6.4 112.4 340 ± 16 4.7 113.5
HQC 2216 ± 201 9.1 110.7 2182 ± 253 11.6 109.1
DRV LOQ 155 ± 12 7.5 103.5 149 ± 15 10.1 99.4
LQC 625 ± 77 12.3 104.2 611 ± 15 2.4 101.8
MQC 1887 ± 68 3.6 104.8 1949 ± 52.6 2.7 108.3
HQC 8626 ± 531 6.1 107.8 8374 ± 829 9.9 104.7
ETV LOQ 51.7 ± 5.7 11.0 103.4 50.1 ± 5.7 11.3 100.2
LQC 195 ± 25 13.0 97.0 216 ± 31 14.3 108.2
MQC 1648 ± 120 7.3 103.0 1538 ± 178 11.5 96.1
HQC 4283 ± 306 7.1 107.1 4162 ± 298 7.1 104.0
EFV LOQ 153 ± 13 8.7 102.1 148 ± 12 8.1 98.9
LQC 638 ± 50 7.8 106.3 603 ± 53 8.8 99.43
MQC 1835 ± 186 10.2 101.9 1850 ± 125 6.7 102.8
HQC 8177 ± 787 9.72 102.2 8032 ± 346 4.3 99.6
RGV LOQ 41.9 ± 5.0 12.0 104.8 42.1 ± 4.75 11.2 105.3
LQC 81.9 ± 7.9 9.7 102.4 85.9 ± 8.2 9.6 107.4
MQC 620 ± 51 8.3 103.4 567 ± 18 3.2 94.5
HQC 6098 ± 663 10.9 101.6 6121 ± 254 4.1 102.0
RPV LOQ 19.8 ± 0.9 4.6 99.2 19.7 ± 0.3 1.4 98.5
LQC 43.5 ± 0.8 1.8 87.1 44.9 ± 4.6 12.3 89.7
MQC 264 ± 6.1 2.3 88.0 273 ± 30 11.1 91.0
HQC 935 ± 32 3.5 93.5 882 ± 88 10.0 88.2
LPV LOQ 146 ± 16 10.6 97.3 151 ± 12 7.7 100.4
LQC 620 ± 65 10.5 103.4 570 ± 73 12.9 95.0
MQC 1828 ± 127 7.0 101.6 1841 ± 110 6.0 102.3
HQC 8600 ± 585 6.8 107.5 8039 ± 1049 13.1 99.51
TPV LOQ 529 ± 50 9.4 105.8 517 ± 59 11.4 103.3
LQC 2030 ± 225 10.0 101.5 2040 ± 148 7.3 102.0
MQC 13,962 ± 849 6.1 87.3 14,989 ± 2023 13.5 93.7
HQC 30,761 ± 1981 6.4 102.5 30,102 ± 1469 4.8 100.3
LQC: low quality control; MQC:medium quality control; HQC: high quality control.
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than 0.99. A linear through zero regression was chosen due to good
linear response for all the drugs up to STD 6.
3.1. Speciﬁcity and selectivity
The assay did not show any signiﬁcant interference with antire-
troviral drugs or other concomitant drugs administered to the patients
at therapeutic doses, excluding the overlapping of DTG with RGV, EFV
and ETV with LPV (Figs. 1 and 2). Five drug-free plasma samples did
not show any interfering peaks in the retention time windows,
considering the speciﬁc wavelength for each drug.
3.2. Accuracy, precision, and limit of quantiﬁcation
Method validation results are listed in Table 2 for all analytes. All
observed data [intraday and interday precision as percent relative
standard deviation (RSD%)] were below 15.0%, in line with the FDA
guidelines [27]. A linear response was shown for all drugs up to STD 6
(Table 1). LOQ for each analyte is listed in Table 2.
3.3. Recovery
Multiple aliquots at each of the QC concentrations were assayed;
and the mean recovery of all drugs ranged between 80% and 120%.
3.4. Stability
After three freeze-thaw cycles, the changes in the drug concentra-
tions were less than ± 5%. The run-time stability study showed that
extracted analytes were stable in the autosampler at 20 °C for up to
24 h (deviation within ± 5% compared with the result at 0 h). Long-
term stability tests were in the acceptable range (Table 3).
3.5. Patients samples analysis
The developed method was applied for the determination of DRV
plasma concentration in 371 samples, of which 7.8% were found to
have levels less than the LOQ. The measured DRV trough concentra-
tions ranged from 205 to 13,488 ng/mL, with an inter-individual CV of
70.6% (Fig. 3A). ATV plasma concentrations in 1022 samples were
analysed, of which 13.5% were found to have concentration less than
the LOQ. The measured ATV trough concentrations ranged from 60 to
6144 ng/mL, with an inter-individual CV of 96.8% (Fig. 3B). ETV
plasma concentration was measured in 74 samples, out of which 8.1%
samples were found to have concentration less than the LOQ. The
measured ETV trough concentrations ranged from 53 to 3158 ng/mL
with an inter-individual CV of 85.6% (Fig. 3C). LPV plasma concentra-
tion was measured in 209 samples out of which 16.7% samples were
found to have concentration less than the LOQ. The measured LPV
trough concentrations ranged from 174 to 26,125 ng/mL, with an
Table 3.
Results of the stability studies.
Analytes Levels Freeze–thaw (3 cycles) Autosampler (24 h) Long term (90 days)
Calculated concentration
(μg/mL) (mean ± SD)
RECa
(%)
RSDb
(%)
Calculated concentration
(μg/mL) (mean ± SD)
RECa
(%)
RSDb
(%)
Calculated concentration
(μg/mL) (mean ± SD)
RECa
(%)
RSDb
(%)
ATV LQC 90.86 ± 2.5 100.9 2.7 90.3 ± 1.6 100.4 1.8 90.4 ± 1.7 98.1 1.8
MQC 918.4 ± 44.9 102.0 4.8 914 ± 30.8 102.3 3.3 904.6 ± 38.2 102.3 4.2
HQC 2095.8 ± 82.7 104.7 3.9 2059.4 ± 92.5 97.6 4.4 1995.8 ± 40.5 103.4 2.0
DTG LQC 49.8 ± 1.8 99.7 3.7 50.83 ± 2.0 101.6 4.0 50.6 ± 2.2 101.2 4.5
MQC 297.1 ± 12.2 99.0 4.1 298.82 ± 12.5 99.6 4.2 304.6 ± 14.8 101.5 4.8
HQC 1979 ± 110.5 98.9 5.5 2042.8 ± 68.1 102.1 3.3 2067 ± 59.7 103.3 2.9
DRV LQC 607.2 ± 23.6 101.2 3.8 608.7 ± 29.9 101.5 4.9 603.3 ± 29.8 100.5 4.9
MQC 1819.1 ± 35.3 101.1 1.9 1821.8 ± 94.5 101.2 3.1 1820.6 ± 46.7 101.1 2.6
HQC 8034.9 ± 144.5 100.4 1.8 8033.7 ± 162.8 100.4 2.0 8059.0 ± 93.5 100.7 1.1
ETV LQC 195.6 ± 8.4 97.8 4.3 200.56 ± 9.3 100.2 4.6 195.2 ± 7.3 97.6 3.8
MQC 1603.1 ± 75.3 100.1 4.7 1619.8 ± 52.0 101.2 3.2 1620.7 ± 42.9 101.2 2.6
HQC 3005.3 ± 89.4 100.1 2.9 2011.4 ± 89.9 100.4 2.3 3009.4 ± 81.7 100.3 2.7
EFV LQC 597.6 ± 27.6 99.6 4.6 609.8 ± 25.8 101.6 4.2 582.8 ± 25.3 97.1 4.3
MQC 1824.9 ± 54.3 101.3 3.0 1835.2 ± 44.8 101.9 2.4 1794.6 ± 31.4 99.7 1.4
HQC 7983.0 ± 111.8 99.7 1.4 7899.0 ± 611 98.7 0.8 7915.7 ± 115.8 98.9 1.4
RGV LQC 81.2 ± 5.6 101.9 4.0 82.1 ± 3.2 102.5 3.9 83.4 ± 3.6 104.2 4.3
MQC 585.4 ± 17.2 97.5 2.9 579.1 ± 12.0 96.5 2.1 585.5 ± 20.1 97.6 3.4
HQC 5933.1 ± 81.6 98.8 1.4 5961 ± 96.4 99.1 1.6 5931.1 ± 95.4 98.8 1.6
RPV LQC 51.66 ± 2.4 103.3 4.6 51.48 ± 2.0 102.9 3.9 50.7 ± 2.2 101.4 4.3
MQC 290.1 ± 13.3 96.7 4.6 296.2 ± 14.2 98.7 4.8 298 ± 13.5 99.3 4.5
HQC 984.9 ± 23.9 98.4 2.4 971.6 ± 26.5 97.1 2.7 1016.1 ± 37.1 101.6 3.6
LPV LQC 575.8 ± 26.3 95.9 4.5 588.1 ± 21.5 98.0 3.7 597.4 ± 26.9 99.5 4.5
MQC 1853.9 ± 51.6 102.9 2.7 1755.7 ± 35.1 97.5 2.0 1761.7 ± 37.5 97.8 2.1
HQC 8076.6 ± 104.5 100.9 1.3 8122.6 ± 35.3 101.5 0.4 8063.0 ± 110.6 100.9 1.3
TPV LQC 2049.7 ± 89.4 102.4 4.3 2074 ± 71.4 103.7 3.4 2038.7 ± 95.5 101.9 4.6
MQC 16,031.6 ± 177.7 100.1 1.1 16,280.8 ± 415.7 101.7 2.5 16,171.0 ± 505.8 101.1 3.1
HQC 30,650.1 ± 1205.3 102.1 3.9 30,048.7 ± 1096 100.2 3.6 30,862.4 ± 3.5 102.8 3.5
LQC=low quality control, MQC=medium quality control, HQC=high quality control.
a REC (%)=calculated concentration/spiked concentration×100%.
b RSD (%)=SD/calculated concentration×100%.
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inter-individual CV of 66.6% (Fig. 3D). EFV plasma concentration was
measured in 207 samples, out of which 12.6% samples were found to
have concentration less than the LOQ. The measured EFV trough
concentrations ranged from 454 to 10,078 ng/mL, with an inter-
individual CV of 65.5% (Fig. 3E). Out of 408 RGV samples measured,
17.1% samples were found to have concentrations less than the LOQ.
The measured RGV trough concentrations ranged from 42 to 9814 ng/
mL, with an inter-individual CV of 158.63% (Fig. 3F). Out of 12 TPV
samples measured, 58.3% samples were found to have concentrations
less than the LOQ. The measured TPV trough concentrations ranged
from 14,450 to 28,065 ng/mL, with an inter-individual CV of 29.3%
(Fig. 3G). The measured RPV trough concentrations ranged from 22 to
173 ng/mL, with an inter-individual CV of 48.0% (Fig. 3H) in 48
samples and no samples were found below the LOQ level. The
measured DTG trough concentrations ranged from 649 to 2878 ng/
mL with an inter-individual variability of 60.8% in 3 samples. The same
distribution was also observed for the other sampling time points: DTG
concentrations at 1, 2, 3 and 4 h after the morning drug intake ranged
from 1835 to 3420 ng/mL (CV, 30.4%), from 2112 to 5666 ng/mL (CV,
45.1%), from 2836 to 6462 ng/mL (CV, 40.2%) and from 2167 to
5195 ng/mL (CV, 40.1%), respectively (Fig. 3I).
4. Discussion
As discussed in the introduction, several HPLC–UV methods are
available in the literature for the simultaneous quantiﬁcation of
antiretroviral drugs in human plasma. However, for the ﬁrst time we
reported here the development and validation of an HPLC–UV assay to
quantify the 9 antiretroviral compounds including DTG and RPV with
accuracy and precision. This bio-analytical method is now being
successfully applied to measure antiretroviral plasma concentrations
for therapeutic purposes.
Under our laboratory conditions, all drugs appeared to be stable
when subjected to the freeze/thaw cycles, in comparison with freshly
prepared controls. Moreover, long-term stability data suggested that all
analytes remained suﬃciently stable under our current storage condi-
Fig. 3. Box-plot of (A) DRV (n=342), (B) ATV (n=885), (C) ETV (n=68), (D) LPV (n=174), (E) EFV (n=181), (F) RGV (n=344), (G) TPV (n=5), (H) RPV (n=48) and (I) DTG (n=3),
where n=number of samples above LOQ.
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tions (−60 °C). The stability of extracted samples at room temperature
(20 °C) or within the autosampler was found to be stable over the
period of analysis. This HPLC–UV SPE assay had a short run time of
25 min per cycle with simple gradient, making it suitable for a high-
throughput TDM, whereby large numbers of samples were processed
quickly and eﬃciently. This is of high value in a clinical setting where
laboratory analyses have to be optimised based on the time-eﬃciency
and reliability.
Emergence of drug-resistant HIV-1 strains and problems of long-
term tolerability of some anti-HIV compounds can jeopardise eﬃcacy
and acceptability of existing anti-HIV medications. DTG and RPV are
among the most recent and promising anti-HIV molecules. Both drugs
have been shown to be highly eﬀective in multi-treated patients and
found to be well tolerated. DTG and the P450(CYP)3A4 inhibitor, RPV,
have the high potential for the interactions with other antiretroviral
agents, notably with protein inhibitors and maraviroc [29,30]. RGV
and ETV also have a high potential for drug interactions, being
substrates and inducers of CYP3A4 [31,32]. Patients administered
with DTG and/or RPV are also given other antiretroviral compounds;
therefore, the measurement of plasma concentrations of the diﬀerent
drugs in the same antiretroviral regimen is necessary. Our method is of
particular clinical value as it allows a quick and reliable assessment of
the plasma level of these drugs, although the clinical usefulness of TDM
of DTG and RPV and their interactions with other co-administered
drugs still need to be investigated further.
Our assay method included widely prescribed protein inhibitors,
non-nucleoside reverse-transcriptase inhibitors and integrase inhibi-
tors [33]. The choice for the limits of their ranges was based on the
highest values reported in the clinical reports and pharmacokinetic
studies. Reliability, costs, ruggedness, sensitivity and reproducibility
are key points of measurement of drug plasma concentrations. Our
assay, relying on SPE coupled with a high-sensitive Waters UV
detector, was simple and less expensive in terms of consumables and
instrumentation when compared with other methods developed on
LC–MS or LC–MS/MS.
The relative accuracy of all QCs at three diﬀerent concentration
levels and intraday and interday precision study support both the
accuracy and precision of our procedure. The choice of a speciﬁc
wavelength for each drug (Table 1) was based on the need for adequate
sensitivity and high speciﬁcity. An example is ETV and RPV for which
quantiﬁcation at 305 nm was chosen to ensure the absence of inter-
ferences and better sensitivity. The absence of interfering peaks,
excluding the overlapping of DTG with RGV and EFV, ETV with
LPV, allows accurate measurement of drugs plasma concentrations.
The co-elution of DTG and RGV, occurring with our method because of
the similar retention time, is not an issue as both drugs belong to the
same class and hence are highly unlikely to be prescribed together. Co-
elution of LPV and EFV can be tackled by running two diﬀerent assays
or by analysing either one of them in a single assay.
5. Conclusion
The HPLC–UV method described here allows an accurate and
reproducible simultaneous quantiﬁcation of nine antiretroviral agents
in plasma. Good extraction eﬃciency and low limit of quantiﬁcation
make this a suitable method for use in clinical trials and for TDM. This
method has been successfully applied to our routine TDM and
pharmacokinetics studies in HIV-infected patients.
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